Safety of intravenous (IV) NEPA and oral NEPA for prevention of CINV in patients (pts) with breast cancer (BC) receiving anthracycline/cyclophosphamide (AC) chemotherapy (CT).

被引：0

作者：

Schwartzberg, Lee S.

Voisin, Daniel

Rizzi, Giada

Patel, Kamal

Aapro, Matti S.

机构：

[1] West Canc Ctr, Memphis, TN USA

[2] Helsinn Healthcare SA, Lugano, Switzerland

[3] CARTI Canc Ctr, Little Rock, AR USA

[4] Clin Genolier, Genolier, Switzerland

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

11594

引用

页数：2

共 50 条

[31] Quality of life data of breast cancer patients receiving a fixed combination of netupitant/palonosetron (NEPA) for prevention of chemotherapy-induced nausea and vomiting - A real life study
Schilling, Joerg
Busch, Steffi
Stefek, Andrea
Muller, Eberhard
Schwickerath, Juergen
Altmann, Falk
Hollander, Martin
Karthaus, Meinolf
CANCER RESEARCH, 2020, 80 (04)
[32] Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in non-anthracycline/cyclophosphamide (AC)-based moderately emetogenic therapy (MEC).
Powers, Daniel
Hesketh, Paul Joseph
Schwartzberg, Lee Steven
Modiano, Manuel R.
Arora, Sujata
Schnadig, Ian D.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (29)
[33] Single-dose NEPA versus 3-day aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with risk factors receiving moderately emetogenic chemotherapy (MEC)
Zelek, L.
Debourdeau, P.
Bourgeois, H.
Wagner, J. P.
Brocard, F.
Lefeuvre-Plesse, C.
Chauffert, B.
Leheurteur, M.
Bachet, J-B.
Simon, H.
Mayeur, D.
Jovenin, N.
Scotte, F.
ANNALS OF ONCOLOGY, 2021, 32 : S1175 - S1175
[34] Efficacy and Safety of Oral NEPA (Netupitant/Palonosetron), the First Fixed-Combination Antiemetic, in Patients With Gynecological Cancers Receiving Platinum-Based Chemotherapy
Bosnjak, Snezana M.
Stamatovic, Ljiljana
Borroni, Maria Elisa
Rizzi, Giada
Jordan, Karin
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 (06) : 1153 - 1161
[35] Quality of life under and efficacy of NEPA as CINV prophylaxis in patients with gastrointestinal cancer receiving highly or moderately emetogenic chemotherapy -Results of a German prospective non-interventional study
Karthaus, M.
Oskay-Oezcelik, G.
Zahn, M. -O
Haas, S.
Kuhn, T.
Schilling, J.
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 213 - 213
[36] Comparative trial of oral granisetron and intravenous ondansetron in patients receiving chemotherapy for breast cancer
Mabro, M
Kerbrat, P
BULLETIN DU CANCER, 1999, 86 (03) : 295 - 301
[37] Integrated analysis of efficacy and safety of palonosetron (PALO) 0.75 mg IV for preventing chemotherapy-induced nausea and vomiting (CINV) in anthracycline and cyclophosphamide (AC/EC) combination chemotherapy in Japan: PALO Japanese breast cancer cooperative study group.
Suzuki, Y.
Tokuda, Y.
Inoue, K.
Aogi, K.
Saito, M.
Yanagita, Y.
CANCER RESEARCH, 2009, 69 (02) : 280S - 280S
[38] Evaluation of sustained antiemetic efficacy over repeated cycles of anthracycline-cyclophosphamide (AC)-based chemotherapy: A phase 3 study of NEPA, a fixed-dose combination of netupitant and palonosetron for prevention of chemotherapy-induced nausea and
Aapro, Matti
Rugo, Hope
Rizzi, Giada
CANCER RESEARCH, 2015, 75
[39] Efficacy of NEPA for prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving highly emetogenic chemotherapy and usefulness of adding olanzapine for prior grade 2 or higher emesis
Na, J.
Park, K.
ANNALS OF ONCOLOGY, 2024, 35 : S1604 - S1604
[40] Randomized, placebo-controlled trial of saforis for prevention and treatment of oral mucositis in breast cancer patients receiving anthracycline-based chemotherapy
Peterson, Douglas E.
Jones, James B.
Petit, Robert G., II
CANCER, 2007, 109 (02) : 322 - 331

← 1 2 3 4 5 →